摘要
目的 :探讨用全身化疗联合同步脑放疗治疗NSCLC(非小细胞肺癌)脑转移的临床效果。方法 :对2011年2月~2013年2月期间我院收治的80例NSCLC脑转移患者的临床资料进行回顾性研究。我们将这80例患者随机分为观察组和对照组,每组各有40例患者。我院使用全身化疗联合序贯脑放疗的方法对对照组患者进行治疗,使用全身化疗联合同步脑放疗的方法对观察组患者进行治疗。治疗结束后,比较两组患者治疗的效果和生存的时间。结果 :经过治疗,观察组患者病情的总缓解率为20%,对照组患者病情的总缓解率为22.5%。两组患者病情的总缓解率大体相同,二者相比差异无显著性(p>0.05)。观察组患者平均的生存时间为3.5±2.3个月,对照组患者平均的生存时间为3.6±1.1个月。两组患者平均的生存时间大体相同,二者相比差异无显著性(p>0.05)。观察组患者1年的生存率37.5%,对照组患者1年的生存率为17.5%。观察组患者1年的生存率明显高于对照组患者,二者相比差异具有显著性(P<0.05)。结论 :用全身化疗联合同步脑放疗治疗NSCLC脑转移可有效地提高患者的1年生存率。此疗法值得在临床上推广使用。
Objective: to analysis the feasibility in the treatment of systemic chemotherapy in NSCLC synchronous brain radiotherapy in the treatment of brain metastases. Method: a total of 80 cases in our hospital were divided into control group and observation group, the patients in the control group the main clinical chemotherapy sequential brain radiotherapy in the treatment of patients in the observation group, the implementation of major systemic chemotherapy synchronous brain radiotherapy treatment, and the treatment effect was observed in two groups. Results: the total remission rate of two group the difference was not significant(P > 0.05), there were no significant differences in the median PFS of two groups of patients(P > 0.05); but the observation group, 1 years survival was significantly higher than the control group, the difference has statistical significance(P < 0.05). Conclusion: chemotherapy synchronous brain radiotherapy for brain metastasis of NSCLC effect, safety and feasibility of good, worthy of clinical use.
